NCT05544240

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With Advanced/Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Williams Cancer Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Conditions

• Metastatic Cancer
• Metastatic Breast Cancer
• Metastatic Lung Cancer
• Solid Tumor
• Cancer

Interventions

Type	Name	Description
DRUG	SV-101	SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Timeline

• Start date: 2023-02-01
• Primary completion: 2025-07-31
• Completion: 2025-12-31
• First posted: 2022-09-16
• Last updated: 2025-04-06

Locations

1 site across 1 country: Mexico